CURE Pharmaceutical has purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals Inc., a Wexford biopharmaceutical company engaged in the acquisition, development and commercialization of branded 505(b)(2) pharmaceutical products. This note represents an initial step toward a potential acquisition of the company and the exclusive rights to Coeptis’ approved drug Consensi®, the first fixed-dose combination drug for the treatment of comorbid osteoarthritis and hypertension.
CURE, Los Angeles area drug delivery and development company, and Coeptis entered into a non-binding term sheet in furtherance of an acquisition, for which the final terms and valuation are to be determined.
“The planned acquisition has the potential to accelerate our 505(b)(2) drug pipeline and expedite our growth, with a planned 2020 launch of Consensi,” CURE CEO Rob Davidson said, in a statement. “Consensi’s potential to reduce pill burden for patients fits our core mission to improve drug delivery and medication adherence.”
